Company attributes
Other attributes
BiOrion is a Dutch clinical-stage biopharmaceutical company that engages in developing PET-imaging diagnostics and targeted radiotherapeutics for fibrotic diseases. It is currently developing a PET-imaging diagnostic for liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for advanced CMS4 colon cancer. Its platform and drug development engine are based on proprietary PDGF-ß-receptor medium affinity binding bicyclic peptides and PDGF-ß-receptor high affinity VHH nanobodies.
The company is testing its first PET imaging diagnostic in a clinical study in patients with either liver or heart fibrosis. When appropriate, the company intends to extend the program to patients who are with either lung fibrosis or colon cancer.
BiOrion runs two active development programs: Cardiscan®, a PET imaging diagnostic where the PET radionuclide 68-Gallium is conjugated to a PDGF-ß-receptor binding bicyclic peptide to identify patients with cardiac fibrosis and Oncoluthera®, where the radionuclide 177-Lutetium is conjugated to the identical single domain antibody.
